AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 82 min read$TLRY

Tilray Brands swings to $40M loss as revenue rises

Tilray Brands reported a net loss of $40.0 million for Q2 2026, despite revenue growth to $257.1 million. Gross profit rose to $77.5 million, but operating loss was $24.1 million. Cannabis revenue declined, while beverage revenue increased. The company issued shares to repay debt and amended credit agreements to ease covenant testing.

Original reporting
stocktitan.net
Published Oct 8, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TLRY
Bearish
high confidence
Mentioned
$TLRY
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TLRYBearishHigh
01

Why it matters

The earnings miss is likely to trigger a short‑term price decline, though the revenue increase may soften the move.

02

Market read

First‑report earnings release for a mid‑cap cannabis company; directly relevant to TLRY traders and sector participants.

03

What to watch

The sale of the 90% stake in Colcanna and covenant amendment may improve balance‑sheet flexibility.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

Tilray Brands filed its Form 10‑Q for the quarter ended Aug 31 2026, disclosing financial results and recent equity actions.

Company-level read

Ticker impact

$TLRYBearishHigh confidence
Context

Tilray Brands reported Q3 2026 net loss of $40M despite revenue growth to $257.1M, a primary earnings disclosure.

Expected impact

likely pressure as market prices in larger-than-expected loss and cash burn

Evidence & confidence

The loss contrasts with prior quarter profit and exceeds typical expectations for a revenue‑up beat, prompting sell pressure.

Market effects

Sector

Cannabis sector may see broader weakness as a mid‑cap loss highlights earnings volatility.

Regional

North American cannabis stocks could face short‑term sell pressure.

Global

Limited to investors with exposure to TLRY and related cannabis equities.

Counterpoint

What could challenge this read

Revenue growth could support a longer‑term rebound if cost controls improve.

Key entities

  • company
    Tilray Brands, Inc.

    US‑listed cannabis and beverage producer.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min